REFERENCES
- Kanner R E, Anthonisen N R, Connett J E. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164:358–364. [PUBMED], [INFOTRIEVE], [CSA]
- Donaldson G C, Seemungal T A, Bhowmik A, Wedzicha J A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847–852. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Andersson F, Borg S, Jansson S A, Jonsson A C, Ericsson A, Prutz C, Ronmark E, Lundback B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96:700–708. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123:784–791. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Cydulka R K, McFadden E R Jr, Emerman C L, Sivinski L D, Pisanelli W, Rimm A A. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156:1807–1812. [PUBMED], [INFOTRIEVE], [CSA]
- Seemungal T A, Donaldson G C, Paul E A, Bestall J C, Jeffries D J, Wedzicha. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Critl Care Med 1998; 157:1418–1422. [CSA]
- Spencer S, Calverley P M, Burge P S, Jones P W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23:698–702. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Calverley P M, Spencer S, Willits L, Burge P S, Jones P W. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003; 124:1350–1356. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Spencer S, Jones P W. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58:589–593. [PUBMED], [INFOTRIEVE], [CROSSREF]
- van der M T, Willemse B W, Schokker S, Ten Hacken N H, Postma D S, Juniper E F. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003; 1:13. [CROSSREF]
- Pauwels R A, Buist A S, Calverley P MA, Jenkins C R, Hurd S S. Global strategy for the diagnosis,management and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1256–1276. [PUBMED], [INFOTRIEVE], [CSA]
- National Institute for Clinical Excellence. Chronic obstructivepulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59:i1–i232. [CROSSREF]
- Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166:329–332. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rengo F, Imperiale C, Bellia V, Catalano F, Scichilone N, Pistelli R, et al. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003; 22:444–449. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Anthonisen N R, Manfreda J, Warren C P, Hershfield E S, Harding G K, Nelson N A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196–204. [PUBMED], [INFOTRIEVE]
- Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117:398S–401S. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J 2001; 17:928–933. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Seemungal T A, Donaldson G C, Bhowmik A, Jeffries D J, Wedzicha J A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1608–1613. [PUBMED], [INFOTRIEVE], [CSA]
- Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum B. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:1819–1823. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A, Maslen T K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320:1297–1303.
- Calverley P M, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912–919. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jones P W, Willits L R, Burge P S, Calverley P M. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease. Eur Respir J 2003; 21:68–73. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Griffiths T L, Burr M L, Campbell I A, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor P J, Payne N, Newcombe R G, Ionescu A A, Thomas J, Tunbridge J. Results at 1 year of out-patient multidisciplinary pulmonary rehabilitation. Lancet 2000; 355:362–368. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Casaburi R, Mahler D A, Jones P W, Wanner A, San P G, Zuwallack R L, Menjose S S, Serby C W, Witek T. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217–224. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Vincken W, Van Noord J A, Greefhorst A P, Bantje T A, Kesten S, Korducki L, Anderson J, Maden C. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19:209–216. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449–456. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74–81. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mahler D A, Wire P, Horstman D, Chang C N, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084–1091. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]